Being tested
Fumarates / NRF2: reduce relapses and new lesions in relapsing and progressive MS
relapsing and progressive MS · Fumarates / NRF2
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 4
- Running now
- 2
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 127
No controlled trial has reported a result yet.
Other linked trials: 4
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 4
These linked trials do not set the status.
- A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)Ongoing
Phase 4 · 2025 · Not randomised
- SURV-SEPStopped, other reason
Phase 4 · 2017 · Not randomised
- DESIRE MSOngoing
Phase 3 · 2026 · Compared with ocrelizumab, ofatumumab, rituximab
- FUSIONResult in a paper, not read yet
Phase 2 · 2023 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 5 → 4
- 2026-10-28Trials: 3 → 5
- 2026-10-27First listed as Being tested
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error